NASDAQ: IMMP
Immutep Ltd Stock

$1.71-0.02 (-1.16%)
Updated Apr 30, 2025
IMMP Price
$1.71
Fair Value Price
N/A
Market Cap
$248.91M
52 Week Low
$1.32
52 Week High
$3.34
P/E
-8.22x
P/B
2.29x
P/S
46.12x
PEG
N/A
Dividend Yield
N/A
Revenue
$6.92M
Earnings
-$27.25M
Gross Margin
100%
Operating Margin
-398.29%
Profit Margin
-398.6%
Debt to Equity
0.06
Operating Cash Flow
-$28M
Beta
0.96
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IMMP Overview

Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine IMMP's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
IMMP
Ranked
#193 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important IMMP news, forecast changes, insider trades & much more!

IMMP News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IMMP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMMP is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IMMP is good value based on its book value relative to its share price (2.29x), compared to the US Biotechnology industry average (4.45x)
P/B vs Industry Valuation
IMMP is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more IMMP due diligence checks available for Premium users.

Valuation

IMMP fair value

Fair Value of IMMP stock based on Discounted Cash Flow (DCF)

Price
$1.71
Fair Value
$0.07
Overvalued by
2,337.38%
IMMP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IMMP price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-8.22x
Industry
-162.28x
Market
29.18x

IMMP price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
2.29x
Industry
4.45x
IMMP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMMP's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IMMP's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMMP's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$113.2M
Liabilities
$6.1M
Debt to equity
0.06
IMMP's short-term assets ($109.29M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMMP's short-term assets ($109.29M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMMP's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IMMP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
IMMP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMMP vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
IMMPC$248.91M-1.16%-8.22x2.29x
SLRN$248.75M+0.82%-0.99x0.54x
DBVTD$246.78M-0.77%-1.58x85.90x
AVIRD$252.30M0.00%-1.48x0.57x
CRVSD$244.61M-0.83%-3.52x7.51x

Immutep Stock FAQ

What is Immutep's quote symbol?

(NASDAQ: IMMP) Immutep trades on the NASDAQ under the ticker symbol IMMP. Immutep stock quotes can also be displayed as NASDAQ: IMMP.

If you're new to stock investing, here's how to buy Immutep stock.

What is the 52 week high and low for Immutep (NASDAQ: IMMP)?

(NASDAQ: IMMP) Immutep's 52-week high was $3.34, and its 52-week low was $1.32. It is currently -48.73% from its 52-week high and 29.55% from its 52-week low.

How much is Immutep stock worth today?

(NASDAQ: IMMP) Immutep currently has 1,455,589,575 outstanding shares. With Immutep stock trading at $1.71 per share, the total value of Immutep stock (market capitalization) is $248.91M.

Immutep stock was originally listed at a price of $23.33 in Apr 19, 2012. If you had invested in Immutep stock at $23.33, your return over the last 13 years would have been -92.67%, for an annualized return of -18.21% (not including any dividends or dividend reinvestments).

How much is Immutep's stock price per share?

(NASDAQ: IMMP) Immutep stock price per share is $1.71 today (as of Apr 30, 2025).

What is Immutep's Market Cap?

(NASDAQ: IMMP) Immutep's market cap is $248.91M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Immutep's market cap is calculated by multiplying IMMP's current stock price of $1.71 by IMMP's total outstanding shares of 1,455,589,575.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.